Cite
Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
MLA
Uemura, Hirotsugu, et al. “Safety and Efficacy of Apalutamide in Japanese Patients with Metastatic Castration‐sensitive Prostate Cancer Receiving Androgen Deprivation Therapy: Final Report for the Japanese Subpopulation Analysis of the Randomized, Placebo‐controlled, Phase III TITAN Study.” International Journal of Urology, vol. 29, no. 6, June 2022, pp. 533–40. EBSCOhost, https://doi.org/10.1111/iju.14843.
APA
Uemura, H., Arai, G., Uemura, H., Suzuki, H., Aoyama, J., Hatayama, T., Ito, M., Lefresne, F., McCarthy, S., Mundle, S., He, J., & Chi, K. N. (2022). Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study. International Journal of Urology, 29(6), 533–540. https://doi.org/10.1111/iju.14843
Chicago
Uemura, Hirotsugu, Gaku Arai, Hiroji Uemura, Hiroyoshi Suzuki, Junya Aoyama, Tomoyoshi Hatayama, Miku Ito, et al. 2022. “Safety and Efficacy of Apalutamide in Japanese Patients with Metastatic Castration‐sensitive Prostate Cancer Receiving Androgen Deprivation Therapy: Final Report for the Japanese Subpopulation Analysis of the Randomized, Placebo‐controlled, Phase III TITAN Study.” International Journal of Urology 29 (6): 533–40. doi:10.1111/iju.14843.